Article Document Academic Article Information Content Entity Continuant Continuant Journal Article Entity Entity Generically Dependent Continuant 2025-05-11T03:54:50 RDF description of Anticoagulation for venous thromboembolism. What are the current options? - http://repository.healthpartners.com/individual/document-rn18350 Ambulatory Care Warfarin/therapeutic use Anticoagulants/*therapeutic use Heparin/*therapeutic use 2022-02-21T22:48:57.408-06:00 22094 document-rn18350 Pulmonary Embolism/*drug therapy Anticoagulation for venous thromboembolism. What are the current options? 10.3810/pgm.2000.09.15.1232 Thrombolytic Therapy 4 108 Heparin, Low-Molecular-Weight/*therapeutic use Venous Thrombosis/*drug therapy 13757 public <p>Venous thromboembolism remains an important cause of considerable morbidity and mortality. Low-molecular-weight heparin appears to be a safe and effective alternative to unfractionated heparin for inpatient treatment. In addition, we recommend considering its use in outpatient treatment in selected patients. When warfarin therapy is initiated, the starting dose should approximate the suspected maintenance dose. The optimal length of anticoagulation after an initial episode of venous thromboembolism is 6 months unless a persistent risk factor is identified. Thrombolytic therapy for hemodynamically stable patients remains controversial, primarily because of the potential for devastating complications.<p> Contraindications Postgraduate Medicine